Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426763 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
A Phase 2 study of Hereditary Angioedema, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT01426763: Completed Phase 2 study of Hereditary Angioedema, sponsored by Shire.
NCT01426763 is a Phase 2 study of Hereditary Angioedema that has completed, run by Shire. The registered enrollment target is 12 participants, below the 75-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01426763, a Phase 2 study of Hereditary Angioedema, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objectives of the study are to: 1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE) who previously participated in CINRYZE Study 0624-200 (NCT01095497) 2. Characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered CINRYZE with rHuPH20 3. Assess the immunogenicity of CINRYZE following subcutaneous (SC) administration of CINRYZE with rHuPH20
Conditions Studied
Interventions
- BIOLOGICAL CINRYZE with rHuPH20
Study Locations (4)
Arizona
- ViroPharma Investigational Site - Scottsdale
California
- ViroPharma Investigational Site - Walnut Creek
Georgia
- ViroPharma Investigational Site - Atlanta
Texas
- ViroPharma Investigational Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-09-12 |
| Est. Completion | 2011-11-28 |
| Phase | Phase 2 |
What the finished NCT01426763 record still lists
NCT01426763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 75-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which CINRYZE with rHuPH20 is the first listed.
NCT01426763 reports a single indexed study location in Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01426763 about?
NCT01426763 is a clinical study titled "A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase". The objectives of the study are to: 1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE) who previously participated in CINRYZE Study 0624-200 (NCT01095497) 2. Characterize the phar...
What is the current status of trial NCT01426763?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-09-12. Estimated completion is 2011-11-28.
What conditions does trial NCT01426763 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT01426763?
The interventions under investigation include: CINRYZE with rHuPH20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01426763?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01426763 being conducted?
This trial has 4 study locations across Arizona, California, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01426763's enrollment target sits among peer trials
12 14th of 14 higher than 1 of 14 other Hereditary Angioedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hereditary Angioedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
COMPLETED · Phase 2
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
RECRUITING · Phase 4
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI